An Open-Label, 2-Part, Single Dose, Randomized Study to Evaluate the Pharmacokinetics of a Probe Formulation of MK-0663B (etoricoxib/tizanidine MR) in Healthy Adult Subjects.

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.0 个研究点目标入组 56 人开始时间: 2012年10月31日最近更新: 2020年1月13日

试验速览

暂无简介。

•BMI < 30kg/m2
•-Female of reproductive potential to have negative pregnancy test and agree to use double-barrier contraception
•-Good health based on medical history, physical examination, vital sign measurements, ECG and laboratory assessments
•-Non smoker

•-History of emotional problems or clinically significant psychiatric disorder within 5yrs
•-Clinically significant disease/disorder of any body systems
•-Creatinine clearance of <80mL/min
•-History of neoplastic disease
•-Breast feeding mother
•-History of stroke, chronic seizures or major neurological disorder
•-Current use of prescription/non-prescription medication (includes oral contraception)-Consumes excessive amounts of alcohol
•-Consumes excessive amounts of caffeine
•-History of significant or severe allergies or anaphylactic reaction
•-History of serious adverse experiences related to non-steroidal anti-inflammatory drug
•-Regular user of illicit drugs

发起方

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.